PDCD1 and non-small cell lung carcinoma: However, another study on NSCLC patients treated with nivolumab found the PDCD1 (PD1) 804C>T SNP was associated with reduced odds of any grade treatment-related toxicities, though this result lacked validation in a subsequent cohort, casting uncertainty on its clinical relevance in predicting toxicity [288].